Abstract:Abstract Persistent infection with high-risk human papillomaviruses (HPV) types is essential for the development of cervical cancer and its immediate precursor, cervical intraepithelial neoplasia 3 (CIN3). However, HPV infection alone is not sufficient to promote cervical carcinogenesis, thus it is hypothesized that the progression to invasive disease is dependent on viral and host factors. For example, it is well established that HPV integration into the host genome is a signature of invasive cervical cancer (ICC). Also, HPV genomes have CpG sites scattered throughout their genes that, with advancing disease, are increasingly methylated by the host cell's DNA methyltransferases. This methylation may alter the expression patterns of viral genes that are relevant to transformation. The goal of the current study was to investigate the landscape of viral-host integration and associated methylation in CIN and ICC. DNA from the lesions of patients diagnosed with either CIN or ICC was captured utilizing HPV and target gene enrichment and next-generation sequencing. DNA libraries were prepared using SureSelectXT Methyl-Seq Target Enrichment Kit (Agilent Technologies) and hybridized with a custom SureSelectXT Library (Agilent Technologies) designed to target 63 HPV types and xGen Lockdown Probes (Integrated DNA Technologies) designed to target 6 cancer-relevant genes. Library samples were pooled and sequenced using the Illumina HiSeq 2000. Bisulfate treated sequence reads obtained from Illumina Hi-Seq 2000 were analyzed by MethylCoder that generates per-base resolution of methylation data. In MethylCoder, the Genomic short-read nucleotide alignment program (GSNAP) was used for aligning short reads into reference genomes (HPV and hg19). For each CpG site, the methylation rate was calculated as the percentage of unconverted cytosines in each sample. In support of previous work, we found that multiple HPV types exhibited integration into various host genes in ICC. Also, HPV integration occurs in different patterns within the same gene. For example, in one tumor, HPV16 exhibited three distinct integrations into the PVT1 oncogene. Global methylation patterns were found to be unique among HPV types and samples, yet preliminary analysis suggests that the percent methylation in HPV may track with that of the host genome. Further, the overall methylation pattern of the virus was significantly different in CIN versus ICC. Here we provide a discussion of specific nonrandom integration sites across multiple ICC samples and representative HPV methylation profiles from CIN and ICC samples. Our data provide novel insights into the HPV CpG methylation sites and gene targets at viral-cellular junctions of different HPV types from CIN through ICC, thus potentially identifying new biomarkers for use in the screening and diagnosis of cervical cancer. Citation Format: Marissa Iden, Samantha Fye, Yi-Wen Huang, Pengyuan Liu, Janet S. Rader. HPV integration and methylation patterns in cervical intraepithelial neoplasia and invasive cervical cancer via HPV capture and high-throughput sequencing. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3173. doi:10.1158/1538-7445.AM2014-3173

HPV Integration: a Precise Biomarker for Detection of Residual/recurrent Disease after Treatment of CIN2-3

Testing for Viral DNA Integration among HPV-positive Women to Detect Cervical Precancer: an Observational Cohort Study

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

Genome-wide profiling of the human papillomavirus DNA integration in cervical intraepithelial neoplasia and normal cervical epithelium by HPV capture technology

Abstract 3173: HPV Integration and Methylation Patterns in Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer Via HPV Capture and High-Throughput Sequencing

Extended Human Papilloma Virus Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2 or Worse in a Cohort Study

The significance of human papillomavirus receptors related genes variants in cervical cancer screening: a longitudinal study of Chinese population

The significance of HPV in the follow-up period after treatment for CIN

Detection of HPV and Human Chromosome Sites by Dual-Color Fluorescence In Situ Hybridization Reveals Recurrent HPV Integration Sites and Heterogeneity in Cervical Cancer

Comprehensive Mapping of the Human Papillomavirus (HPV) DNA Integration Sites in Cervical Carcinomas by HPV Capture Technology.

Infection and integration of high-risk human papillomavirus in HPV-associated cancer cells

Identification of Novel Genomic Hotspots and Tumor-Relevant Genes Via Comprehensive Analysis of HPV Integration in Chinese Patients of Cervical Cancer

HPV L1 and P16 Expression in CIN1 to Predict Future CIN2+

Integrated HPV Genomes Tend to Integrate in Gene Desert Areas in the CaSki, HeLa, and SiHa Cervical Cancer Cell Lines.

Value of Liquid-Based Cytology Test Combined with HR-HPV Testing in CIN III after LLETZ During Follow-Up

Abstract 2280: HPV integration identifies emerging oncogenes and carcinogenic mechanisms, potentially indicating tumor recurrences

Association Between Recurrence of High-grade Squamous Intraepithelial Lesions of the Uterine Cervix and p16, C-myc and PIK3CA Proteins—A Single-center Retrospective Study

Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1–2 lesions

A Study of Thinprep Cytologic Test Combined with Human Papilloma Virus Hybrid CaptureⅡ DNA Test and Biopsy-Control in Cervical Lesions

Performance of Different Follow-Up Strategies and Genotype-Based Recurrence Risk After Treatment of Cervical High-Grade Squamous Intraepithelial Lesion

HPV 16/18 E7 oncoprotein detection as a promising triage strategy for HPV 16/18‐positive patients: A prospective multicenter study with a 2‐year follow up